Xiaoyan Lin
A5100717455- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- Esophageal Cancer Research and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer survivorship and care
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Head and Neck Cancer Studies
- Pancreatic and Hepatic Oncology Research
- Medical Research and Treatments
- Metastasis and carcinoma case studies
- Palliative Care and End-of-Life Issues
- Family Support in Illness
- Ginseng Biological Effects and Applications
- Ferroptosis and cancer prognosis
- Anesthesia and Sedative Agents
- Childhood Cancer Survivors' Quality of Life
- Cancer Research and Treatments
- Natural product bioactivities and synthesis
- Colorectal and Anal Carcinomas
Fudan University
2024-2025
Fujian Medical University
2006-2024
Union Hospital
2015-2024
Shandong Provincial Hospital
2011-2024
Shandong First Medical University
2021-2024
Fujian Provincial Cancer Hospital
2018-2024
Virginia Tech
2024
Mount Elizabeth Hospital
2024
Children’s Hospital of Fudan University Xiamen Branch
2024
Nanjing Medical University
2024
Purpose There is currently no standard treatment strategy for patients with advanced metastatic gastric cancer experiencing progression after two or more lines of chemotherapy. We assessed the efficacy and safety apatinib, a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, in gastroesophageal junction adenocarcinoma whom at least prior chemotherapy had failed. Patients Methods This was randomized, double-blind, placebo-controlled phase III trial. from 32 centers...
As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) for recurrent or metastatic NPC (RM-NPC) refractory standard chemotherapy.In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression unacceptable toxicity. The...
Importance There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is current standard of care first-line treatment recurrent or metastatic NPC (RM-NPC). Objective To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival overall as RM-NPC, compared alone. Design, Setting, Participants JUPITER-02 an international, multicenter, randomized,...
Abstract Background Association of immune-related adverse events with tumor response has been reported. Reactive cutaneous capillary endothelial proliferation (RCCEP) is the most common event related to camrelizumab, an immune checkpoint inhibitor, but lack comprehensive analyses. In this study, we conducted analyses on RCCEP in advanced hepatocellular carcinoma (HCC) patients treated camrelizumab monotherapy. Methods Data were derived from a Chinese nationwide, multicenter phase 2 trial...
Abstract Purpose: Our preclinical work suggests that appropriate angiogenesis inhibition could potentiate PD-1/PD-L1 blockade via alleviating hypoxia, increasing infiltration of CD8+ T cells and reducing recruitment tumor-associated macrophages. We hereby conducted a clinical trial to evaluate this combination in pretreated patients with advanced non–small cell lung cancer (NSCLC). Patients Methods: The study included phase Ib apatinib dose-escalation II expansion cohorts. received at doses...
Background: The incidence of cancer pain increases in discharged patients because discontinued standard treatments and reductions medication adherence. Motivated by the need for better management patients, we developed a mobile phone app (Pain Guard) to provide continuous treatment information feedback suffering from pain.
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus vs first-line treatment GC/GEJC/esophageal adenocarcinoma (EAC). with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive (360 mg Q3W 240...
Hepatocellular carcinoma (HCC) is a malignancy originating from hepatocytes with high rate of distant metastasis and recurrence. HCC prognosis remains poorly understood, although its diagnosis treatment have improved globally. Therefore, it necessary to identify reliable predictive prognostic indicators HCC. gene expression profiles corresponding clinical data were downloaded The Cancer Genome Atlas. Seven lncRNAs (C10orf91, AC011352.3, AC015722.2, AC006372.1, PICSAR, AC110285.3, AP001972.4)...
In the randomized phase III KEYNOTE-181 study, pembrolizumab prolonged overall survival (OS) compared with chemotherapy as second-line therapy in patients advanced esophageal cancer and programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥10. We report a post hoc subgroup analysis of squamous cell carcinoma (ESCC) enrolled Asia, including from China extension study.Three hundred forty Asian advanced/metastatic ESCC were KEYNOTE-181, cohort. Patients randomly assigned : to receive...
Abstract Purpose This investigation sought to examine the efficacy and safety of low-dose apatinib used alongside chemotherapy in clinical management patients with metastatic triple-negative breast cancer (TNBC) within a real-world setting, whilst comparing outcomes those treated solely chemotherapy. Methods case series study analyzed data treatment 163 TNBC who underwent rescue at Medical Oncology Department Clinical Oncology, Fujian Cancer Hospital, School University, China, between...
Our preclinical work suggests that low-dose angiogenesis inhibition could potentiate programmed cell death protein 1 and death-ligand (PD-L1) blockade. In a cohort of our multicenter phase 1b 2 study (NCT03083041), promising antitumor activity was observed with camrelizumab plus apatinib in chemotherapy-pretreated patients advanced nonsquamous NSCLC. We hereby reported the results treatment-naive (cohort 4) from same study. Eligible had untreated NSCLC high tumor mutational burden (TMB)...
Abstract Background Colorectal cancer (CRC) is the third most prevalent in China but few large-scale studies were conducted to understand CRC patients. The current study aimed gain a real-world perspectives of patients China. Methods Using electronic medical records sampled between 2011 and 2016 from 12 hospitals China, retrospective cohort was describe demographics disease prognosis patients, examine treatment sequences among metastatic (mCRC) Descriptive, comparative survival analyses...
Objectives: To describe direct medical costs associated with each line of treatment among metastatic colorectal cancer (mCRC) patients in China.Methods: Electronic records between 2011 and 2016 were extracted from 12 tertiary hospitals China for adult who initiated third-line at least nine months before the end data collection. Direct included wards, diagnostic tests, surgical procedures, special materials, drugs others. Costs assessed by treatment, drug further breakdown receiving...
To explore the effect of programmed death 1 (PD-1) inhibitor combined with apatinib on immune regulation and efficacy therapy in mice bearing gastric cancer (MBGC), to provide a research basis for enhancing benefit immunotherapy advanced (AGC). MBGC were divided into normal saline group (group NS), A), PD-1 inhibitors B) C). Tumor inhibition rates calculated. Cytokine levels expression cells molecules detected, pathological manifestations tumor tissues observed. Group C had smallest volume...